NCT05434000

Brief Summary

The overall goal of this feasibility study is to establish a standard of care stroke prevention program for children with sickle cell anemia in a community hospital by task shifting stroke detection and transcranial Doppler ultrasound screening to nurses. In Nigeria, approximately 150,000 children with sickle cell anemia (SCA) are born annually, accounting for more than half of the total births with SCA worldwide. In comparison, only 1,700 children with SCA are born in the United States annually. An estimated 11% of unscreened and untreated children at increase of strokes with SCA will have at least one stroke by 17 years of age. In high-income countries, evidence-based practices (EBP) for primary stroke prevention in children with SCA involves screening for abnormal transcranial Doppler ultrasound (TCD) velocity (\>200cm/s) coupled with regular blood transfusion therapy for at least one year followed by treatment with hydroxyurea is considered standard care. This strategy decreases the risk of stroke by 92%. Due to safety and availability, regular blood transfusion is not a viable option for primary stroke prevention in most low-income settings, including Nigeria, where \~50% of the 300,000 children with SCA are born. Among each birth cohort, 15,000 children will have stroke annually in Nigeria. The American Society of Hematology (ASH) Central Nervous System Guidelines recommends moderate dose hydroxyurea (20mg/kg) to children with SCA with abnormal TCD measurements, living in resource-constrained settings where regular blood transfusions are not readily available. Our team has demonstrated in a previous trial the feasibility of primary stroke prevention with hydroxyurea in Kano, Nigeria. In 2016, as part of capacity building objective of Stroke Prevention Trial in Nigeria (1R01NS094041-SPRING) at Barau Dikko Teaching Hospital in Kaduna, TCD screening was adopted as standard of care. Before the trial, no TCD screening was done at our trial site in Kaduna. Now, as standard care, physicians at the teaching hospital do TCD screening, however, only 5.4% (1,101/20,040) of the eligible children with SCA living in Kaduna, Nigeria were reached. Clearly, for there to be an appreciable impact on decreasing the stroke rates in children with SCA living in Nigeria and elsewhere, applying the ASH guidelines and a better implementation strategy to increase the TCD reach (proportion of children eligible for TCD screening that are screened) is necessary. Therefore, objective of this physician-mentored application is to conduct an Effectiveness-Implementation Feasibility Trial is to test the test the hypothesis that the task-shifted site for primary stroke prevention team in a community hospital will have a non-inferior effectiveness in identifying children with abnormal TCD measurements when compared to primary stroke prevention team in a teaching hospital in Kaduna, Nigeria. the investigators will conduct i) a needs assessment at the community hospital to identify barriers and facilitators to the intervention, ii) Build capacity for stroke detection and TCD screening and iii) Compare the effectiveness of a physician-based stroke prevention program in a teaching hospital to a task-shifted stroke prevention in a community hospital.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
217

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 6, 2021

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 19, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 27, 2022

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2025

Completed
Last Updated

August 1, 2023

Status Verified

July 1, 2023

Enrollment Period

4.6 years

First QC Date

June 19, 2022

Last Update Submit

July 27, 2023

Conditions

Keywords

Sickle Cell AnaemiaStrokeTranscranial Doppler UltrasoundHydroxyureaTask-shifting

Outcome Measures

Primary Outcomes (2)

  • Reach

    The portion of children than received TCD screening at least once in the community hospital

    1 year

  • Effectiveness

    The proportion of children with abnormal TCD measurement started on hydroxyurea

    1 year

Secondary Outcomes (3)

  • Stroke occurrence

    1 year

  • Clinical events among children on Hydroxyurea

    1 year

  • Clinical events among children not on Hydroxyurea

    1 year

Study Arms (1)

Children with sickle cell anaemia and abnormal TCD values (200cm/s)

OTHER

The children identified with abnormal TCD values will be given hydroxyurea and followed for one year

Drug: Hydroxyurea

Interventions

Children at risk of developing stroke (TCD values\>200cm/s) will be given 20mg/kg of Hydroxyurea

Also known as: Oxyurea
Children with sickle cell anaemia and abnormal TCD values (200cm/s)

Eligibility Criteria

Age2 Years - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children with diagnosis of SCA (HbSS or HbSβthal0)
  • years receiving care at both YDMH (community hospital) and BDTH (teaching hospital).
  • No previous stroke

You may not qualify if:

  • Children with SCA younger than 2 years or older than 16
  • Children with stroke
  • \) Children already on Hydroxyurea

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Barau Dikko Teaching Hospital/Kaduna State University

Kaduna, Nigeria

RECRUITING

Related Publications (2)

  • Bello-Manga H, Haliru L, Ahmed K, Ige S, Musa H, Muhammad-Idris ZK, Monday B, Sani AM, Bonnet K, Schlundt DG, Varughese T, Tabari AM, DeBaun MR, Baumann AA, King AA. Barriers and facilitators to a task-shifted stroke prevention program for children with sickle cell anemia in a community hospital: a qualitative study. Implement Sci Commun. 2024 Jan 15;5(1):10. doi: 10.1186/s43058-023-00534-z.

  • Bello-Manga H, Haliru L, Ahmed K, Ige S, Musa H, Muhammad-Idris ZK, Monday B, Sani AM, Bonnet K, Schlundt DG, Varughese T, Tabari AM, DeBaun MR, Baumann AA, King AA. Barriers and Facilitators to a Task-Shifted Stroke Prevention Program for Children with Sickle Cell Anemia in a Community Hospital: A Qualitative Study. Res Sq [Preprint]. 2023 Jul 3:rs.3.rs-2985921. doi: 10.21203/rs.3.rs-2985921/v1.

MeSH Terms

Conditions

Anemia, Sickle CellStroke

Interventions

Hydroxyurea

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, CongenitalAnemia, HemolyticAnemiaHematologic DiseasesHemic and Lymphatic DiseasesHemoglobinopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

UreaAmidesOrganic Chemicals

Study Officials

  • Halima Bello-Manga, MBBS,MPH

    Barau Dikko Teaching Hospital/Kaduna State University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Halima Bello-Manga, MBBS,MPH

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 19, 2022

First Posted

June 27, 2022

Study Start

January 6, 2021

Primary Completion

July 31, 2025

Study Completion

July 31, 2025

Last Updated

August 1, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will share

The audiences most suitable for these results are persons affected with SCD and their families, health care providers, administrators, policy makers and other researchers in both SCD and implementation science. We believe dissemination of the results from this study will have immediate public health impact. The results will be published in high-impact journals like the New England Journal of Medicine, Lancet, Blood, American Journal of Hematology as well as presentations at National and International Scientific Conferences. The stakeholders in the community and teaching hospitals, and the State ministry of health will be provided with annual updates on study progress and interim results. We will also present study progress to the during the annual World Sickle Cell Day celebration, usually organized by community-based SCD support groups.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
When study is completed
Access Criteria
Access will be granted with permission

Locations